Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy

Annals of Neurology

Volumn 65, Issue 2, 2009, Pages 140-150

  Banno, Haruhiko ^a   Katsuno, Masahisa ^a,b   Suzuki, Keisuke ^a   Takeuchi, Yu ^a   Kawashima, Motoshi ^a   Suga, Noriaki ^a   Takamori, Motoko ^c   Ito, Mizuki ^a   Nakamura, Tomohiko ^a   Matsuo, Koji ^a   Yamada, Shinichi ^a   Oki, Yumiko ^d   Adachi, Hiroaki ^a   Minamiyama, Makoto ^a   Waza, Masaliiro ^a   Atsnra, Naoki ^a   Watanabe, Hirohisa ^a   Fujimoto, Yasushi ^a   Nakashima, Tsutomu ^a   Tanaka, Fumiaki ^a   Doyu, Manabu ^e   Sobue, Gen ^a   more..

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c SHIZUOKA SAISEIKAI GENERAL HOSPITAL   (Japan)

^d Aichi Saiseikai Hospital   (Japan)

^e AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN; LUTEINIZING HORMONE RECEPTOR; MUTANT PROTEIN; PLACEBO; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN INSENSITIVITY SYNDROME; ARTHRALGIA; ARTICLE; AUTOPSY; BIOACCUMULATION; BRAIN STEM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRICOPHARYNGEUS MUSCLE; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; ERECTILE DYSFUNCTION; FATIGUE; FLUOROGRAPHY; FOLLOW UP; FRACTURE; GLUCOSE BLOOD LEVEL; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INJECTION SITE LUMP; KENNEDY DISEASE; LOW BACK PAIN; MALE; MOTONEURON; MYALGIA; NEURALGIA; OPEN STUDY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCROTUM; SIDE EFFECT; SKIN BIOPSY; SPINAL CORD; SWALLOWING; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIDEOFLUOROGRAPHY;

EID: 62549084738     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21540     Document Type: Article

References (51)

1. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968;18:671-680.
2. Sperfeld AD, Karitzky J, Brummer D, et al. X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 2002;59: 1921-1926.
3. Sobue G, Hashizume Y, Mukai E, et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989;112(pt l):209-232.
4. Katsuno M, Adachi H, Tanaka F, Sobue G. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives. J Mol Med 2004;82:298-307.
5. Fischbeck KH. Kennedy disease, J Inherit Metab Dis 1997;20: 152-158.
6. Katsuno M, Adachi H, Waza M, et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 2006;200:8-18.
7. Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006;129:1446-1455.
8. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular arrophy. Nature 1991;352:77-79.
9. Tanaka F, Doyu M, Ito Y, et al. Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum Mol Genet 1996;5: 1253-1257.
10. Andrew SE, Goldberg YP, Hayden MR. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. Hum Mol Genet 1997;6:2005-2010.
11. Doyu M, Sobue G, Mukai E, er al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992; 32:707-710.
12. Shimada N, Sobue G, Doyu M, et al. X-linked recessive bulbospinal neuronoparthy: clinical phenotypes and CAG repeat size in androgen receptor gene. Muscle Nerve 1995; 18: 1378-1384.
13. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000;23:217-247.
14. Ross CA. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002;35:819-822.
15. Gatchel |R, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005;6: 743-755.
16. Adachi H, Katsuno M, Minamiyama M, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005;128:659-670.
17. Banno H, Adachi H, Katsuno M, et al. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 2006;59: 520-526.
18. Sobue G, Doyu M, Kachi T, et al. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 1993;117:74-78.
19. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EX. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002;59:770-772.
20. Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002;35: 843-854.
21. Katsuno M, Adachi H, Doyu M, er al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003; 9:768-773.
22. Takeyama K, Ito S, Yamamoto A, et al. Androgen-dependenr neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002;35:855-864.
23. Chevalier-Larsen ES, O'Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 2004;24:4778-4786.
24. Shimohata F, Kimura F, Nishizawa M, et al. Five year follow up of a patient with spinal and bulbar muscular atrophy treated with leuprorelin. J Neurol Neurosurg Psychiatry 2004;75: 1206-1207.
25. Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin In-vestig Drugs 2007;16:1851-1863.
26. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115.
27. Niijima T, Aso Y, Akaza H, et al. [Clinical phase I and phase 11 study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative+ + Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR.]. Hinyokika Kiyo 1990; 36:1343-1360.
28. Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994;48: 930-967.
29. Ohashi Y, Tashiro K, Itoyama Y, et al. [Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version]. No To Shinkei 2001; 53:346-355.
30. Chahin N, Klein C, Mandrekar J, Sorenson E. Natural history of spinal-bulbar muscular atrophy. Neurology 2008;70: 1967-1971.
31. Morin LG. Creatine kinase: re-examination of optimum reaction conditions. Clin Chem 1977;23:1569-1575.
32. Logemann JA, Pauloski BR, Rademaker AW, et al. Temporal and biomechanical characteristics of oropharyngeal swallow in younger and older men. J Speech Lang Hear Res 2000;43: 1264 -1274.
33. Logemann JA, Evaluation and treatment of swallowing disorders. 2nd ed. Austin, TX: Pro-Ed, 1998.
34. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995;378:403-406.
35. Terao S, Sobue G, Hashizume Y, et al. Age-related changes in human spinal ventral horn cells with special reference to the loss of small neurons in the intermediate zone: a quantitative analysis. Acta Neuropathol 1996;92:109-114.
36. Suzuki K, Katsuno M, Banno H, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008;131:229-239.
37. Nishie M, Mori F, Yoshimoto M, et al. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropadiol Appl Neurobiol 2004;30:546 -554.
38. Tanaka F, Reeves MF, Ito Y, et al. Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor-gene expression level. Am J Hum Genet 1999;65:966-973.
39. Takeuchi Y, Katsuno M, Banno H, et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 2008;38:964-971.
40. Fowler JE Jr, Gottesman JE, Reid CF, et al. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 2000;164:730-734.
41. Taylor JP, Hardy J, Fischbeck KH. Foxic proteins in neurodegenerative disease. Science 2002;296:1991-1995.
42. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007;30:575-621.
43. Zhou ZX, Lane MV, Kemppainen JA, et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 1995;9:208-218.
44. Jacob P, Kahrilas PJ, Logemann JA, et al. Upper esophageal sphincter opening and modulation during swallowing. Gastroenterology 1989;97:1469 -1478.
45. Lazarus CL, Logemann JA, Rademaker AW, et al. Effects of bolus volume, viscosity, and repeated swallows in nonsrroke subjects and stroke patients. Arch Phys Med Rehabil 1993;74: 1066-1070.
46. Williams RB, Grehan MJ, Hersch M, et al. Biomechanics, diagnosis, and treatment outcome in inflammatory myopathy presenting as oropharyngeal dysphagia. Gut 2003;52: 471-478.
47. Ertekin C, Aydogdu I, Yuceyar N, et al. Pathophysiological mechanisms of oropharyngeal dysphagia in amyotrophic lateral sclerosis. Brain 2000;123(pt 1):125-140.
48. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurorrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996;46:1244-1249.
49. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 1984;311: 1281-1286.
50. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61:32-38.
51. Dejager S, Bry-Gauillard H, Bruckert E, et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002;87:3893-3901.